These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 25795375)
21. Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men. Behkar A; Garmaroudi G; Nasimi M; Yousefi S; Khosravi H; Kianfar N; Murrell DF; Daneshpazhooh M Int J Womens Dermatol; 2022 Mar; 8(1):e004. PubMed ID: 35620025 [TBL] [Abstract][Full Text] [Related]
23. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases. Ohata C; Ishii N; Koga H; Fukuda S; Tateishi C; Tsuruta D; Furumura M; Hashimoto T J Am Acad Dermatol; 2015 Jul; 73(1):50-5. PubMed ID: 25896671 [TBL] [Abstract][Full Text] [Related]
28. The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use? Wijayanti A; Zhao CY; Boettiger D; Chiang YZ; Ishii N; Hashimoto T; Murrell DF Acta Derm Venereol; 2017 Jan; 97(1):24-31. PubMed ID: 27244117 [TBL] [Abstract][Full Text] [Related]
29. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Bernard P; Vaillant L; Labeille B; Bedane C; Arbeille B; Denoeux JP; Lorette G; Bonnetblanc JM; Prost C Arch Dermatol; 1995 Jan; 131(1):48-52. PubMed ID: 7826096 [TBL] [Abstract][Full Text] [Related]
30. [Bullous autoimmune diseases of the oral mucosa]. Vaillant L Rev Stomatol Chir Maxillofac; 1999 Oct; 100(5):230-9. PubMed ID: 10604215 [TBL] [Abstract][Full Text] [Related]
31. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865 [TBL] [Abstract][Full Text] [Related]
33. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus. Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP Front Immunol; 2019; 10():2571. PubMed ID: 31781098 [TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis of patient-reported physical and psychological stressors as trigger factors in autoimmune bullous disease. Davis AE; Nathanson J; Attwood K; Sinha AA; Seiffert-Sinha K Arch Dermatol Res; 2024 Aug; 316(8):515. PubMed ID: 39133440 [No Abstract] [Full Text] [Related]
35. Incidence of autoimmune bullous diseases in Serbia: a 20-year retrospective study. Milinković MV; Janković S; Medenica L; Nikolić M; Reljić V; Popadić S; Janković J J Dtsch Dermatol Ges; 2016 Oct; 14(10):995-1005. PubMed ID: 27767273 [TBL] [Abstract][Full Text] [Related]
36. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature. Sami N; Ahmed AR Dermatology; 2001; 202(4):293-301. PubMed ID: 11455140 [TBL] [Abstract][Full Text] [Related]
37. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari. Atzori L; Deidda S; Aste N G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046 [TBL] [Abstract][Full Text] [Related]